Here's the secret behind Cochlear Limited's monster returns

The Cochlear Limited (ASX:COH) share price could be volatile this week.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Don't be fooled by the recent dip in share price, hearing device maker Cochlear Limited (ASX: COH) is in great shape.

The company is expected to announce a full year profit of between $210m and $225m when it reports later this month, growth of 10-20%.

One giant reason to buy

One of the things I like most about Cochlear is its huge return on equity (ROE) which completely blows away the 10% average for U.S. healthcare product companies.

Return on equity shows us how effectively a company is using investor funds. Cochlear is among the best-in-class when it comes to the ROE measure, just short of CSL Limited (ASX: CSL).

Here's how Cochlear's ROE has tracked over the last five years:

Cochlear Limited 2016 2015 2014 2013 2012
Net Income ($m) 189 146 94 133 57
Total equity ($m) 449 355 329 355 385
ROE 42% 41% 29% 38% 15%

Source: Cochlear Limited annual reports

It's worth pointing out that I haven't made any adjustments to reported net income. In 2012 for example net income includes a one-time $101 million cost associated with product recalls.

It's also interesting to see the significant increase in equity reported in 2016. This was in part because Cochlear's higher earnings left it with more retained earnings.

Breaking down return on equity

To see where Cochlear's huge 42% ROE comes from we can break it out into three components using the DuPont analysis:

  • Net profit margin (Net Income ÷ Revenue) 0.17
  • Asset Turnover (Revenue ÷ Assets) 1.18
  • Equity Multiplier (Assets ÷ Shareholders' Equity) 2.13
  • Return on equity = (0.17) x (1.18) x (2.13) = 42.1%

We can quickly see that a big driver of the returns is Cochlear's use of debt to fund assets; the high equity multiplier. Without this, if Cochlear didn't leverage its assets with borrowed money, ROE would only be 19.7%.

That would still be a pretty good return! And because Cochlear has strong cash flows to service the interest I would not be concerned by current debt levels.

However if a comparable investment had a higher unleveraged return, for example Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), we may prefer to buy it.

Foolish takeaway

Cochlear's business focuses on all the right areas to deliver strong returns for investors. Quality products drive strong profit margins, high volumes accelerate the turnover of assets and reasonable use of debt leverages returns upwards.

This is a company I would love to own, and I will certainly be watching for any further weakness in share price.

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. You can follow him on Twitter @Regan_Invests. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »